What happened with Grail's cancer screening trial?

Grail's three-year cancer screening trial failed to meet its main goal of statistically significant reduction in late-stage cancer diagnoses.

What are the implications of the trial failure for the Galleri test?

While the U.S. FDA approval may not be at material risk, the trial failure could impact decisions by the Centers for Medicare and Medicaid Services regarding coverage policies for the Galleri test.

Home / Business and Economy / Grail Cancer Test Trial Misses Key Goal

Grail Cancer Test Trial Misses Key Goal

Q: How did Grail's stock react to the trial results?

Grail's shares plunged nearly 50% in premarket trading on Friday, February 20, 2026, following the trial outcome.

20 Feb

•

Summary

Grail's shares dropped nearly 50% after a trial failed.
The three-year cancer screening trial did not meet its primary goal.
The Galleri test's success is crucial for potential Medicare coverage.

Grail (GRAL.O) experienced a significant stock decline, with shares falling nearly 50% in premarket trading on Friday, February 20, 2026. This sharp drop followed the news that the company's extensive three-year cancer screening trial had failed to achieve its main objective.

The trial, conducted across the National Health Service (NHS) with over 142,000 participants aged 50 to 77, was designed to assess if Grail's Galleri test could reduce late-stage cancer diagnoses and improve early detection. This data was intended to inform a potential screening program in England.